FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Sanofi Pasteur | acne

Sanofi aims for acne vaccine in new pact

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Lured by the $3 billion acne treatment market, Sanofi Pasteur has inked a collaboration deal with with the University of California, San Diego to develop an immunological approach to fighting the skin condition.

Current treatments for acne use benzoyl peroxide and oral or topical antibiotics, which the company notes can disrupt the skin's balance and lead to more resistant forms of the bacteria. The collaboration will attempt to develop a vaccine that will neutralize Propionibacterium acnes factors in inflammation. Financial details of the two-year agreement weren't disclosed.

"This opportunity could provide an immunotherapeutic product with significant benefits and a novel mechanism of action to address an unmet medical need," noted Dr. Elias Zerhouni, president of Global R&D, in a release. "This investigational vaccine and treatment may lead to a better solution for the many who suffer from this skin disease."

- here's the Sanofi release

Related Article:
Pimple treatments pocked with poor supporting science


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Sanofi Pasteur   acne